All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior consent of the JoongAng Ilbo | Tel: 1577-0510
JoongAng Ilbo Co., Ltd. | Address: 48-6 Sangamsan-ro, Mapo-gu, Seoul, Republic of Korea
Business registration number: 110-81-00999 | CEO & Publisher: Park Chang-hee | Executive Editor: Choi Ji-young
Mail order business report number: 2020-Seoul Mapo-3838 | Online newspaper registration No: 서울,아55177
Date of Registration: 2023. 11. 21 | Juvenile Protection Manager: Park Hyunyoung
![A bird's-eye view of SK bioscience's vaccine facility in Songdo, Incheon [SK BIOSCIENCE]](https://image.koreajoongangdaily.com/11774043.jpg?imageId=11774043&width=240&height=184&format=webp&format=jpg)
![SK bioscience CEO Ahn Jae-yong, right, and John Herrmann, chief legal officer of Novavax, sign a licensing deal for the manufacture of the U.S. company's Covid-19 vaccine. [SK BIOSCIENCE]](https://image.koreajoongangdaily.com/10740873.jpg?imageId=10740873&width=240&height=184&format=webp&format=jpg)
![Boxes of U.S.-based biotechnology company Novavax's Covid-19 vaccine are moved from an SK Bioscience plant in Andong, North Gyeongsang, on Thursday. Earlier in the day, the Food and Drug Safety Ministry allowed the domestic release of 840,000 doses of the vaccine. [NEWS1]](https://image.koreajoongangdaily.com/10550220.jpg?imageId=10550220&width=240&height=184&format=webp&format=jpg)
![A researcher at the Korean Vaccine Research and Development Center for Public Vaccines in Cheongju, North Chungcheong, in December testing the effect of SK Bioscience Covid-19 vaccine. It is the first to be tested after finishing phase 3 clinical trial. [YONHAP]](https://image.koreajoongangdaily.com/11626278.jpg?imageId=11626278&width=240&height=184&format=webp&format=jpg)
![This image provided by Pfizer shows the company's Covid-19 Paxlovid pills, which will be prescribed in Korea starting Friday. [NEWS1]](https://image.koreajoongangdaily.com/11541947.jpg?imageId=11541947&width=240&height=184&format=webp&format=jpg)
![President Moon Jae-in meets Stanley Erck, CEO of U.S. vaccine producer Novavax, at the Blue House in Seoul on Tuesday. [YONHAP]](https://image.koreajoongangdaily.com/11200551.jpg?imageId=11200551&width=240&height=184&format=webp&format=jpg)
![People get AstraZeneca shots at a vaccination center in Gwangju, as the rollout of the temporarily-suspended AstraZeneca vaccines resumed Monday. [YONHAP]](https://image.koreajoongangdaily.com/10385919.jpg?imageId=10385919&width=240&height=184&format=webp&format=jpg)
![Nurses train for Covid-19 shots at the Korean Nurses Association in central Seoul Tuesday. These nurses will be dispatched to hospitals and treatment centers for Covid-19 patients. The first inoculations in Korea kick off on Feb. 26. [YONHAP]](https://image.koreajoongangdaily.com/10359508.jpg?imageId=10359508&width=240&height=184&format=webp&format=jpg)
![President Moon Jae-in, center, talks with SK Group Chairman Chey Tae-won, far right, Wednesday while touring a SK Bioscience factory in Andong, North Gyeongsang. SK Bioscience is in talks with Novavax to sign a technology transfer agreement involving the American drug company’s Covid-19 vaccine. If signed, the vaccine will be produced locally. The Andong factory is also where Covid-19 vaccines of AstraZeneca are being produced after SK Bioscience inked a contract manufacturing organization deal with the Britain-based drug company. [YONHAP]](https://image.koreajoongangdaily.com/11439219.jpg?imageId=11439219&width=240&height=184&format=webp&format=jpg)